0.0265
0.0015 (6.0%)
0.0015 (6.0%)
Upgrade to Real-Time
Market Closed
| Volume | 205,684 |
|
|||||
| News | - | ||||||
| Day High | 0.027 | Low High |
|||||
| Day Low | 0.0257 | ||||||
Best deals to access real time data! |
|
Small Cap Basic
Monthly Subscription
for only
|
|
Ultimate Trader (Monthly)
Monthly Subscription
for only
|
|
DDE w/Realtime (Monthly)
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Tauriga Sciences Inc (QB) | TAUG | OTCMarkets | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
 |
|
|---|---|---|---|---|
| 0.0015 | 6.0% | 0.0265 | 16:30:13 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 0.0268 | 0.0257 | 0.027 | 0.0265 | 0.025 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 33 | 205,684 | $ 0.026467 | $ 5,444 | - | 0.0225 - 0.185 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 15:51:53 | 101 | $ 0.0265 | USD |
Period:
Draw Mode:
Tauriga Sciences Inc (QB) Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 7.57M | 285.70M | 203.49M | $ - | $ - | - | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| 39.41k | $ - | - | - | - |
Tauriga Sciences (QB) News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical TAUG Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.03 | 0.03 | 0.0225 | 0.0278567 | 561,703 | -0.0035 | -11.67% |
| 1 Month | 0.0355 | 0.0449 | 0.0225 | 0.033354 | 728,682 | -0.009 | -25.35% |
| 3 Months | 0.0321 | 0.07 | 0.0225 | 0.0381881 | 852,081 | -0.0056 | -17.45% |
| 6 Months | 0.054 | 0.07 | 0.0225 | 0.0400492 | 694,305 | -0.0275 | -50.93% |
| 1 Year | 0.145 | 0.185 | 0.0225 | 0.0872552 | 1,072,542 | -0.1185 | -81.72% |
| 3 Years | 0.0459 | 0.365 | 0.0153 | 0.0801087 | 1,245,184 | -0.0194 | -42.27% |
| 5 Years | 0.00455 | 1.00 | 0.000098 | 0.0111136 | 5,900,722 | 0.02195 | 482.42% |
Tauriga Sciences (QB) Description
| Tauriga Sciences, Inc. (TAUG) is a revenue generating, diversified life sciences company, engaged in several major business activities and initiatives. The company manufactures and distributes several proprietary retail products and product lines, mainly focused on the Cannabidiol ("CBD") and Cannabigerol ("CBG") Edibles market segment. The main product line, branded as Tauri-Gum™, consists of a proprietary supplement chewing gum that is Kosher certified, Halal certified, and Vegan Formulated (CBD Infused Tauri-Gum™ Flavors: Mint, Blood Orange, Pomegranate), (CBG Infused Tauri-Gum™ Flavors: Peach-Lemon, Black Currant) & (Vitamin C + Zinc "Immune Booster" Tauri-Gum™ Flavor: Pear Bellini). The Company has also developed and sells a Gelatin Free, CBD Infused Gum Drop Product, branded as: Tauri-Gummies™. The Company's commercialization strategy consists of a broad array of retail customers, distributors, and a fast-growing E-Commerce business segment (E-Commerce website: www.taurigum.com). Please visit our corporate website, for additional information, as well as inquiries, at http://www.tauriga.com Complementary to the Company's retail business, is its ongoing Pharmaceutical Development initiative. This relates to the development of a proposed Pharmaceutical grade version of Tauri-Gum™, for nausea regulation (specifically designed for the following indication: Patients Subjected to Ongoing Chemotherapy Treatment). On March 18, 2020, the Company announced that it had filed a provisional U.S. patent application covering its pharmaceutical grade version of Tauri-Gum™. The Patent, filed with the U.S.P.T.O. is Titled "MEDICATED CBD COMPOSITIONS, METHODS OF MANUFACTURING, AND METHODS OF TREATMENT". On December 18, 2020 the Company disclosed that it had entered into a Master Services Agreement with CSTI to lead the Company's clinical development efforts. |